Value of the CD25+ CD16+ cell determination in defining the prognosis of operable breast cancer patients.
The immunologic status of 40 breast cancer patients with operable disease and 50 healthy women was studied at the Division of Medical Oncology of the 2nd Medical School in Naples. Skin tests and lymphocyte subpopulation determination were performed. The same tests were repeated after surgery in the cancer patients. At the same time, the immunologic modifications during chemotherapy (CMF) were studied in a further 25 premenopausal breast cancer patients. The cancer patients did not show significantly different reactivity to recall antigens, nor did surgery or chemotherapy modify this parameter. The breast cancer patients showed a significantly higher CD4+/CD8+ ratio (2.07 +/- 1.06 vs. 1.56 +/- 0.58; p < 0.05) and a higher percentage of CD16+ cells (15.7 +/- 7 vs. 9.1 +/- 6; p < 0.001), than controls. Patients without axillary lymph node involvement showed higher CD4+/CD8+ ratio, CD16+ and CD25+ percentage than the N+ patients. The percentage of CD25+ cells (expressing functional IL-2 receptor) and CD16+ cells proved to be predictive of early relapse: in 14 patients who had relapsed at a 37 month median follow-up, mean CD25+ and CD16+ cell values at diagnosis were significantly lower than those in the remaining 26 (CD25+: 0.87 +/- 0.7 vs. 2.44 +/- 2.19, p < 0.01; CD16+: 9.4 +/- 6 vs. 17.3 +/- 5, p < 0.001). These data suggest that a functional activation may occur in operable breast cancer patients except those with axillary node metastatization (especially when more than 3 axillary lymph nodes are involved).(ABSTRACT TRUNCATED AT 250 WORDS)
Iaffaioli
R V
RV
Cattedra di Oncologia Medica Università di Cagliari.
Frasci
G
G
Rinaldi
L
L
Del Vecchio
L
L
Tortoriello
A
A
Facchini
G
G
Perone
V
V
Montesarchio
V
V
Vacca
C
C
Vaia
F
F
D000328:Adult; D000368:Aged; D001365:Axilla; D001943:Breast Neoplasms / Q000276:immunology* / Q000473:pathology / Q000601:surgery*; D016516:CD4-CD8 Ratio; D005260:Female; D006801:Humans; D006968:Hypersensitivity, Delayed / Q000276:immunology; D008207:Lymphatic Metastasis; D008875:Middle Aged; D011379:Prognosis; D017452:Receptors, IgG / Q000032:analysis*; D015375:Receptors, Interleukin-2 / Q000032:analysis*
D017452:Receptors, IgG; D015375:Receptors, Interleukin-2